Diabetic Medication for Endo/Metabolic: 76.9% of denials overturned
In 13 California IMR decisions from 2026 to 2026, reviewers overturned 10 (76.9%). In the last five years: 76.9% of 13. 13 were medical-necessity disputes.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2026 | 13 | 76.9% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 7 | 100.0% | 76.9% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Fiasp Penfill. Per the U.S. Food and Drug Administration (FDA), Fiasp is indicated to improve glycemic control in patients with diabetes mellitus. Medical literature recognizes Fiasp as a rapid‑acting insulin option for mealtime glucose management. In this case, the patient has type 1 diabetes mellitus and requires …”
“The physician reviewer found that a patient has requested authorization and coverage for Ozempic. The U.S. Food and Drug Administration (FDA) approves Ozempic (semaglutide) to lower blood sugar in patients with type 2 diabetes mellitus. Medical literature supports semaglutide as an effective therapy for improving glycemic control in type 2 diabetes mellitus. Per the medical records, the patient has a …”
“The physician reviewer found that a patient has requested authorization and coverage for Mounjaro. The American Diabetes Association (ADA) considers glucagon‑like peptide‑1 (GLP‑1) or GLP‑1/glucose‑dependent insulinotropic polypeptide (GIP) agonist receptors a first‑line therapy for the treatment of diabetes mellitus type 2, as these agents are advantageous for patients with multiple cardiovascular risk factors. In this case, the patient has a …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement and prospective authorization and coverage for Ozempic. Studies show the impact of semaglutide on preventing diabetes progression. However, such trials specifically enroll only patients with obesity and prediabetes, which this patient does not have. Per the records, the patient’s highest hemoglobin (HB) A1c level is …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Diabetic Medication denials for Endo/Metabolic overturned?
In 13 California IMR decisions from 2026 to 2026, reviewers overturned 10 (76.9%). In the last five years: 76.9% of 13. 13 were medical-necessity disputes.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.